Evidence map›Paper›PMID 40833438›Full record

ArticleMolecular diversity2026

Discovery of 7-azaindole-3-acrylamide inhibitors of inflammasomes/IL-1β for the treatment of inflammatory bowel disease.

Yuyun Yan, Xiuxiu Zhang, Ruiwen Wu, Xiangting Liang, Yiming Luo, Jie Yang, Dan Wu, Geng Lin, Ping Sun, Zhongjin Yang and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuyun Yan *School of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin, 300384, China.
Xiuxiu Zhang *School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Ruiwen Wu *School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Xiangting LiangSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Yiming LuoSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Jie YangSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Dan WuSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Geng LinSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Ping SunSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China.
Zhongjin YangSchool of Chemistry and Chemical Engineering, Tianjin University of Technology, Tianjin, 300384, China. yangzhj23@tjut.edu.cn.
Wenhui HuSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, China. huwenhui@gzhmu.edu.cn.

Funding

National Natural Science Foundation of China 81803364
6 · The paper itself

Abstract

Currently, a significant proportion of patients with inflammatory bowel disease (IBD) fail to respond to conventional drug therapies such as immunosuppressants and biologic agents. IL-1 signaling blockade is a promising therapeutic strategy for these unresponsive IBD patients. In this study, we identified a novel anti-NLRP3/ IL-1β inhibitor, the 7-azaindole analogue Y19, which exhibits an IC

Indexed as

Anti-Inflammatory AgentsDrug DiscoveryIndolesInflammasomesInflammatory Bowel DiseasesInterleukin-1betaAnimalsColitisDisease Models, AnimalHumansMiceNLR Family, Pyrin Domain-Containing 3 ProteinAnti-Inflammatory AgentsIndolesInflammasomesInterleukin-1betaNLR Family, Pyrin Domain-Containing 3 Protein7-azaindole-3-acrylamideIL-1βInflammasomeInflammatory bowel diseaseInhibitors

Identifiers

PMID40833438

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.